Establishment of a human iPSC line, IISHDOi004-A, from a patient with Usher syndrome associated with the mutation c.2276G>T; p.Cys759Phe in the USH2A gene by Zurita-Díaz, Francisco et al.
Contents lists available at ScienceDirect
Stem Cell Research
journal homepage: www.elsevier.com/locate/scr
Lab Resource: Stem Cell Line
Establishment of a human iPSC line, IISHDOi004-A, from a patient with
Usher syndrome associated with the mutation c.2276G>T; p.Cys759Phe in
the USH2A gene
Francisco Zurita-Díaza,b,c,d,1, María del Carmen Ortuño-Costelaa,b,c,d,1, Ana Moreno-Izquierdod,e,
Liliana Galbisf, José María Millánc,g, Carmen Ayusoc,f, Rafael Garessea,b,c,d,
M. Esther Gallardoa,b,c,d,⁎
a Departamento de Bioquímica, Facultad de Medicina, Universidad Autónoma de Madrid, Spain
b Instituto de Investigaciones Biomédicas “Alberto Sols” (UAM-CSIC), Madrid, Spain
c Centro de Investigación Biomédica en Red (CIBERER), Madrid, Spain
d Instituto de Investigación Sanitaria Hospital 12 de Octubre (i+12), Madrid, Spain
e Servicio de Genética, Hospital 12 de Octubre, Madrid, Spain
fDepartamento de Genética, Instituto de Investigación Sanitaria – Hospital Universitario Fundación Jiménez Díaz (IIS-FJD, UAM), Madrid, Spain
g Instituto de Investigación Sanitaria Hospital La Fe, IIS-La Fe, Valencia, Spain
A B S T R A C T
A human iPSC line, IISHDOi004-A, from ﬁbroblasts obtained from a patient with Usher syndrome, harboring a homozygous mutation in the USH2A gene
(c.2276G>T; p.Cys759Phe) has been generated. Reprogramming factors Oct3/4, Sox2, Klf4, and c-Myc were delivered using Sendai virus.
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Unique stem cell line
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Alternative name(s) of
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RPAB16-FiPS4F3
Institution Instituto de Investigación Sanitaria
Hospital 12 de Octubre, i+ 12
Contact information of
distributor
Dr. M. Esther Gallardo
egallardo.imas12@h12o.es
Type of cell line iPSC
Origin Human
Additional origin info Age: N/A
Sex: Male
Ethnicity if known: Spanish
Cell Source Skin ﬁbroblasts
Clonality Clonal
Method of
reprogramming
Transgene free (Sendai virus)
Genetic Modiﬁcation NO
Type of Modiﬁcation N/A
Associated disease Usher syndrome
Gene/locus Gene USH2A: c.2276G>T; p.Cys759Phe;
Chromosome: 1q41
Method of
modiﬁcation
N/A
Name of transgene or
resistance
N/A
Inducible/constitutive
system
N/A
Date archived/stock
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bank
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Resource utility
Usher syndrome is an autosomal recessive disease involving sen-
sorineural hearing loss, retinitis pigmentosa, and, in some cases, ves-
tibular dysfunction. There is no clinical treatment available for this
disorder. The iPSC line reported here will be very useful for modelling
this disease and for carrying out a high-throughput pharmacological
screening.
Resource details
The human iPSC line, IISHDOi004-A, has been generated using a
non-integrative methodology that involves the use of Sendai viruses
containing the reprogramming factors Oct3/4, Sox2, Klf4, and c-Myc
(Takahashi et al., 2007). For this purpose, ﬁbroblasts from a patient
with Usher syndrome (Millán et al., 2011) have been obtained from a
skin biopsy. These ﬁbroblasts harboured a homozygous mutation in the
USH2A gene (c.2276G>T; p.Cys759Phe). We have also conﬁrmed the
presence of this mutation in the iPSCs (Fig. 1A). IISHDOi004-A iPSC
colonies displayed a typical ES-like colony morphology and growth
behaviour (Fig. 1B) and they stained positive for alkaline phosphatase
activity (Fig. 1C). The endogenous expression of the pluripotency as-
sociated transcription factors OCT4, SOX2, KLF4, NANOG, CRIPTO and
REX1 was evaluated by quantitative real time polymerase chain reac-
tion (qPCR) (Fig. 1H). Immunoﬂuorescence analysis revealed expres-
sion of transcription factors OCT4, NANOG and SOX2, and typical ES
cells surface markers SSEA3, SSEA4, TRA-1-60 and TRA-1-81 (Fig. 1E).
We also conﬁrmed the clearance of the vectors and the exogenous re-
programming factor genes by RT-PCR after eight culture passages
(Fig. 1G). The iPSC line has been adapted to feeder-free culture con-
ditions and a karyotype analysis after more than 20 culture passages
has been performed (Fig. 1F). This analysis displayed a normal (46, XY)
karyotype. We also veriﬁed that the line IISHDOi004-A was derived
from the patient's ﬁbroblasts by DNA ﬁngerprinting analysis (archived
at SCR journal). In addition, the line was conﬁrmed by PCR analysis to
be mycoplasma-negative (Fig. 1D). Finally, the capacity of the
IISHDOi004-A iPSC line to diﬀerentiate into the three germ layers
(endoderm, mesoderm and ectoderm) was evaluated in vitro using an
embryoid body based assay (Fig. 1I).
Materials and methods
Generation of iPSCs
Human ﬁbroblasts from a patient with Usher syndrome harboring
the mutation c.2276G>T; p.Cys759Phe in the USH2A gene were re-
programmed using the CytoTune-iPS 2.0 Sendai reprogramming kit
following the instructions of the manufacturer. IISHDOi004-A line was
maintained and expanded both on feeder and feeder-free conditions as
described in Galera et al., 2016.
Phosphatase alkaline analysis
The iPSC line IISHDOi004-A was seeded on a feeder layer plate.
After one week, direct phosphatase alkaline activity was determined
using the phosphatase alkaline blue membrane substrate solution kit
(Sigma, AB0300), (Table 1).
Mutation analysis
Total DNA from patient's ﬁbroblasts and iPSCs was extracted using a
commercial kit. Subsequently, a PCR was carried out with the primers
shown in Table 2. Following PCR ampliﬁcation, direct sequencing of
amplicons was performed in an ABI 3730 sequencer (Applied Biosys-
tems).
qPCR analysis
Total mRNA was isolated using TRIZOL and 1 μg was used to syn-
thesize cDNA using the Quantitect RT cDNA synthesis kit. One μl of the
reaction was used to quantify by qPCR the expression of the en-
dogenous pluripotency associated genes (OCT4, SOX2, KLF4, NANOG,
CRIPTO and REX1, Table 1). Primers are listed in Table 2 (Aasen et al.,
2008). All the expression values were normalized to the GAPDH gene.
Plots are representative of at least three independent experiments.
Karyotype analysis
Karyotype analyses were carried out using cells with more than
twenty culture passages. Brieﬂy, cells were treated with 10 μg/mL of
Colcemid (Gibco) for 90min at 37 °C, trypsinized, treated with hypo-
tonic solution KCl 0.075M, and ﬁxed with Carnoy's ﬁxative. Cells were
then dropped on a microscope glass slide and dried. Metaphase cells
were G banded using Wright staining. At least 20 metaphases were
karyotyped.
Immunoﬂuorescence analysis
Cells were grown on 0.1% gelatin-coated 35mm culture plates
(81,156, Ibidi), ﬁxed with 4% paraformaldehyde for 30min at RT and
permeabilized using TBS+ (0.1% Triton X-100 in Tris-buﬀered saline,
TBS) for 45min. Then the cells were incubated in TBS++ (3% donkey
serum, 0.3% Triton X-100 in TBS) for two hours at RT. Primary anti-
bodies were applied overnight at 4 °C. Secondary antibodies for two
hours at RT. Nuclei were stained with DAPI (Sigma, 28718-90-3). The
antibodies are listed in Table 2.
In vitro diﬀerentiation assay
The in vitro pluripotency capacity of the line IISHDOi004-A was
tested by spontaneous embryoid body diﬀerentiation. The protocol used
has been described in detail by Galera et al., 2016.
DNA ﬁngerprinting analysis
For DNA ﬁngerprinting analysis the markers D13S317, D7S820,
VWA, D8S1179, D21S11, D19S433, D2S1338 and amelogenin for sex
determination have been ampliﬁed by PCR and analyzed by ABI PRISM
3100 Genetic analyzer and Peak Scanner v3.5 (Applied Biosystems),
(Table 2).
Mycoplasma detection
Mycoplasma detection was performed by PCR analysis using 1mL of
the cell culture supernatant (3 days culture, 90% conﬂuence). Primers
used are speciﬁed in Table 2. The 300 bp band represents a myco-
plasma-positive sample (positive control, C+). The 570 bp band is an
internal control to discard the inhibition of the polymerase.
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Fig. 1. Molecular and functional characterization of the IISHDOi004-A iPSC line.
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Table 2
Reagents details.
Antibodies used for immunocytochemistry/ﬂow-cytometry
Antibody Dilution Company Cat # and RRID
Pluripotency markers Mouse anti-TRA-1-81 1:150 Millipore Cat# MAB4381, RRID: AB_177638
Mouse anti-TRA-1-60 1:150 Millipore Cat# MAB4360, RRID: AB_11211864
Rabbit anti-SOX2 1:100 Thermo Fisher Scientiﬁc Cat# PA1-16968, RRID: AB_2195781
Mouse anti-SSEA4 1:10 Millipore Cat# MAB4304, RRID: AB_177629
Rat anti-SSEA3 1:20 Abcam Cat# ab16286, RRID: AB_882700
Goat anti-NANOG 1:25 R and D Systems Cat# AF1997, RRID: AB_355097
Mouse anti-OCT4 1:100 Santa Cruz Biotechnology Cat# sc-5279, RRID: AB_628051
Diﬀerentiation markers Mouse anti-β tubulin isotype III 1:300 Sigma-Aldrich Cat# T8660, RRID: AB_528427
Mouse anti- AFP 1:300 Sigma-Aldrich Cat# WH0000174M1, RRID: AB_1839587
Mouse anti- SMA 1:400 Sigma-Aldrich Cat# A2547, RRID: AB_476701
Secondary antibodies Cy™2-conjugated AﬃniPure Donkey Anti-Goat IgG (H+ L) 1:50 Jackson ImmunoResearch Labs Cat# 705-225-147, RRID: AB_2307341
Cy™2-conjugated AﬃniPure Goat Anti-Mouse IgG, Fcγ Subclass
2b speciﬁc
1:50 Jackson ImmunoResearch Labs Cat# 115-225-207, RRID: AB_2338749
Cy™2-conjugated AﬃniPure Goat Anti-Rabbit IgG (H+ L) 1:50 Jackson ImmunoResearch Labs Cat# 111-225-144, RRID: AB_2338021
Cy™3-conjugated AﬃniPure Goat Anti-Rat IgM, μ chain speciﬁc 1:250 Jackson ImmunoResearch Labs Cat# 112-165-075, RRID: AB_2338249
Cy™3-conjugated AﬃniPure Goat Anti-Mouse IgG, Fcγ Subclass 3
speciﬁc
1:250 Jackson ImmunoResearch Labs Cat# 115-165-209, RRID: AB_2338698
Cy™3-conjugated AﬃniPure Donkey Anti-Mouse IgM, μ chain
speciﬁc
1:250 Jackson ImmunoResearch Labs Cat# 715-165-020, RRID: AB_2340811
Goat anti-mouse IgG (H+ L), Alexa Fluor 488 1:500 Thermo Fisher Scientiﬁc Cat# A-11029, RRID: AB_2534088
Primers Target Forward/reverse primer (5′-3′)
Pluripotency markers (qPCR) Endo-KLF4 AGCCTAAATGATGGTGCTTGGT / TTGAAAACTTTGGCTTCCTTGTT
Endo-OCT4 GGGTTTTTGGGATTAAGTTCTTCA / GCCCCCACCCTTTGTGTT
Endo-SOX2 CAAAAATGGCCATGCAGGTT / AGTTGGGATCGAACAAAAGCTATT
REX1 CCTGCAGGCGGAAATAGAAC / GCACACATAGCCATCACATAAGG
CRIPTO CGGAACTGTGAGCACGATGT / GGGCAGCCAGGTGTCATG
NANOG ACAACTGGCCGAAGAATAGCA / GGTTCCCAGTCGGGTTCAC
House-Keeping Genes (qPCR) GAPDH GCACCGTCAAGGCTGAGAAC / AGGGATCTCGCTCCTGGAA
Targeted mutation analysis/sequencing USH2A AGTAAGATTGGCCCCCTATGGC / CTCCCTTCAACATTGGGCTTGC
Virus silencing SeV GGATCACTAGGTGATATCGAGC / ACCAGACAAGAGTTTAAGAGATATGTATC
KOS ATGCACCGCTACGACGTGAGCGC / ACCTTGACAATCCTGATGTGG
Klf4 TTCCTGCATGCCAGAGGAGCCC / AATGTATCGAAGGTGCTCAA
c-Myc TAACTGACTAGCAGGCTTGTCG / TCCACATACAGTCCTGGATGATGATG
STR analysis D2S1338 [6-FAM] CCAGTGGATTTGGAAACAGA / ACCTAGCATGGTACCTGCAG
D7S820 [6-FAM] TGTCATAGTTTAGAACGAACTAACG / CTGAGGTATCAAAAACTCAGAGG
D8S1179 [6-FAM] TTTTTGTATTTCATGTGTACATTCG / CGTAGCTATAATTAGTTCATTTTCA
D13S317 [6-FAM] ACAGAAGTCTGGGATGTGGA / GCCCAAAAAGACAGACAGAA
D19S433 [6-FAM] CCTGGGCAACAGAATAAGAT / TAGGTTTTTAAGGAACAGGTGG
D21S11 [6-FAM] GTGAGTCAATTCCCCAAG / GTTGTATTAGTCAATGTTCTCC
VWA [6-FAM] CCCTAGTGGATGATAAGAATAATC / GGACAGATGATAAATACATAGGATGGATGG
Amelogenin [6-FAM] CCCTGGGCTCTGTAAAGAATAGTG / ATCAGAGCTTAAACTGGGAAGCTG
Mycoplasma detection GPO-3 / MGSO GGGAGCAAACAGGATTAGATACCCT / TGCACCATCTGTCACTCTGTTAACCTC
Table 1
Characterization and validation.
Classiﬁcation Test Result Data
Morphology Photography Normal Fig. 1 panel B
Phenotype Qualitative analysis: immunocytochemistry Positive for the pluripotency markers: SSEA3, SSEA4, TRA-
1-81, TRA-1-60, OCT4, NANOG, SOX2
Fig. 1 panel E
Qualitative analysis: alkaline phosphatase
activity
Positive Fig. 1 panel C
Quantitative analysis: gene expression (qPCR) Positive for the pluripotency markers OCT4, KLF4, SOX2,
CRIPTO, NANOG, REX1
Fig. 1 panel H
Genotype Karyotype (G-banding) and resolution 46, XY Resolution 450–500 Fig. 1 panel F
Identity STR analysis DNA proﬁling performed Submitted to SCR journal for
archiving
8 loci, all matched (D2S1338, D7S820, D8S1179,
D13S317, D19S433, D21S11, VWA, amelogenin)
Submitted to SCR journal for
archiving
Mutation analysis (IF
APPLICABLE)
Sequencing Conﬁrmation of the mutation: USH2A c. 2276G>T;
p.Cys759Phe
Fig. 1 panel A
Southern Blot OR WGS N/A N/A
Microbiology and virology Mycoplasma Mycoplasma testing by PCR: negative Fig. 1 panel D
Diﬀerentiation potential Embryoid body formation and directed
diﬀerentiation
Positive for: smooth muscle actin (SMA), β-tubulin (Tuj1)
and alpha-fetoprotein (AFP)
Fig. 1 panel I
Donor screening (OPTIONAL) HIV 1+2 Hepatitis B, Hepatitis C N/A N/A
Genotype additional info
(OPTIONAL)
Blood group genotyping N/A N/A
HLA tissue typing N/A N/A
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